Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 30

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 30
---
 of the underwriter’s over-allotment option).

<div align='center'>S-22</div>

We have paid an expense deposit of $25,000 to the representative, which will be applied against the out-of-pocket accountable expenses that will be paid by us to the underwriters in connection with this offering, and will be reimbursed to us to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).

We have also agreed to pay all expenses relating to the offering, including (a) all filing fees and expenses relating to the registration of the securities to be sold in the offering (including securities sold upon exercise of the underwriter’s over-allotment option) with the Commission; (b) all fees associated with the review of the offering by FINRA and all fees and expenses relating to the listing of such shares of common stock on the Nasdaq Capital Market; (c) the costs of all mailing and printing of the underwriting documents; (d) the costs of preparing, printing and delivering certificates representing the common stock sold in this offering; (e) fees and expenses of our transfer agent; (f) transfer and/or stamp taxes, if any, payable upon the transfer of the shares of our common stock to the underwriter; (g) fees and expenses of our legal counsel and accountants; and (h) for the actual fees and expenses incurred by the Representative, including legal fees of the Representative’s counsel not to exceed $100,000 and the Representative’s other expenses in connection with the offering not to exceed $69,500.

Our total estimated expenses of the offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding underwriting discounts and commissions and excluding the non-accountable expense allowance, are approximately $185,000.

#### Representative’s Warrants
Upon closing of this offering, we have agreed to issue the Representative’s Warrants to the representative as compensation warrants to purchase up to 333,750 shares of common stock (5% of the aggregate number of shares of common stock sold in this offering). The Representative’s Warrants will be exercisable at a per share exercise price equal to $0.375, or 125% of the public offering price per share in this offering. The Representative’s Warrants are exercisable at any time and from time to time, in whole or in part, during the five year period from the commencement of sales of the shares of common stock in this offering.

In addition, the